论文部分内容阅读
目的:探讨莫西沙星治疗老年支原体肺炎患者的临床疗效。方法:收集我院收治的老年支原体肺炎患者80例,年龄60~79岁,随机分为对照组和实验组,每组各40例,两组患者均给予相应常规对症治疗,对照组患者给予红霉素治疗;实验组患者给予莫西沙星治疗。治疗结束后,比较两组患者的退热时间、住院时间、白细胞计数、C反应蛋白水平以及患者的临床总有效率。结果:与治疗前相比,两组患者治疗后的白细胞计数、C反应蛋白水平均显著下降(P<0.05),且实验组患者退热时间以及住院时间较对照组显著缩短(P<0.05),白细胞计数、C反应蛋白水平明显低于对照组(P<0.05),而临床治疗总显著高于对照组(P<0.05)。结论:莫西沙星能显著提高老年支原体肺炎患者的临床疗效。
Objective: To investigate the clinical efficacy of moxifloxacin in the treatment of elderly patients with mycoplasma pneumonia. Methods: 80 elderly patients with mycoplasmal pneumonia who were admitted to our hospital were collected, aged 60-79 years. They were randomly divided into control group and experimental group, 40 cases in each group. The patients in both groups were given conventional symptomatic treatment, while those in control group were given red Moxifloxacin treatment; experimental group of patients given moxifloxacin treatment. After the treatment, the two groups of patients were compared to the antipyretic time, hospital stay, white blood cell count, C-reactive protein level and the patient’s total clinical efficiency. Results: Compared with those before treatment, the white blood cell count and C-reactive protein in both groups were significantly decreased (P <0.05), and the patients in the experimental group had significantly shorter antipyretic time and hospital stay than the control group (P <0.05) , White blood cell count and C-reactive protein were significantly lower than those of the control group (P <0.05), while the total clinical treatment was significantly higher than that of the control group (P <0.05). Conclusion: Moxifloxacin can significantly improve the clinical efficacy of elderly patients with mycoplasma pneumonia.